众生药业：盐酸氨溴索口服溶液药品注册证书获批

Core Viewpoint - The approval of the oral solution of Ambroxol Hydrochloride by the National Medical Products Administration signifies a significant milestone for the company, enhancing its product line in the respiratory treatment sector [1] Group 1: Product Approval - The company has received the drug registration certificate for Ambroxol Hydrochloride oral solution from the National Medical Products Administration [1] - This product is classified as a Category B drug under the medical insurance system in China [1] Group 2: Market Potential - The projected sales for Ambroxol Hydrochloride oral solution in public hospitals and urban pharmacies in China are estimated to be 711 million yuan in 2022, 818 million yuan in 2023, and 850 million yuan in 2024 [1] - The approval indicates that the product has passed the consistency evaluation for chemical generic drugs, which is expected to further enrich the company's offerings in the respiratory treatment market [1]